Integrating oxaliplatin into the management of colorectal cancer

Oncologist

Volumn 6, Issue SUPPL. 4, 2001, Pages 24-28

  Schmoll, Hans Joachim ^a   Cassidy, Jim ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

5 FU; Capecitabine; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; THYMIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

EID: 0034790854     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_4-24     Document Type: Conference Paper

References (18)

1. Oxaliplatin in colorectal cancer: An overview
2. Pharmacokinetics and safety profile of oxaliplatin
3. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
4. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
5. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
6. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
7. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy
8. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
9. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
10. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
11. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
12. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
13. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
14. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
15. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
16. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
17. 24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
18. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study